These COVID-19 Stocks are Still “Strong Buy” Opportunities

[Logo] May 19, 2020 [www.tradewins.com]( Other Exciting News 5 Exciting Low-Risk Ways To Turn Cheap Weekly Options Into Non-Stop Income If you think higher profits require greater risk… think again! My name’s Chris Verhaegh and I’ve been trading since I was in 11th grade. And, even though I started with very little money, trading allowed me to put a high 5-figure deposit down on a house just 6 months out of high school. So, when my son came home from college with $1,189 left in his bank account and used it to follow my Money Tree strategy… generating cash payouts totaling $2,025 in the first two weeks… $3,579 profit by month’s end, (300% monthly return)… I was naturally proud; but not terribly surprised! The 5 low-risk strategies I developed for turning cheap weekly options into non-stop income have been making a lot of very ordinary people extraordinarily rich! [CLICK HERE]( to learn all about the Grand Slam, the Money Tree, the Lit Fuse and 2 more exciting low-risk ways to earn non-stop income… I promise, you won’t be disappointed! Yours for Better Trading, Chris Verhaegh [Click Here Now]( It’s free, so why not? Recent Articles [Intraday Market Mapping - Making Good Systems Better]( by [Lee Gettess]( [TradeWins Author Team]( Tomorrow, you could begin doubling your account every single month starting with one letter. The letter will come from a 20-year trading professional named Ian Cooper. He says, “In 2017, following my trades you would be doubling even tripling your account some months. Let me show you how.” He will show you exactly what to do... and he’ll give you the blueprint for just $1. [Get Daily Trade Alert Now]( About TradeWins [Inside Trading Newsletter]( [Webinars]( [Videos]( [Trading Strategy]( [Options]( [Futures]( [Forex]( [Day Trading]( [Subscription Services]( [E-Books]( [Customer Satisfaction Survey 2018]( These COVID-19 Stocks are Still “Strong Buy” Opportunities by [Ian Cooper]( [image](#) Some of the top biotech companies are now in human trials, and seeing a good deal of progress. Better, as we near better and better results from these companies, their stocks are still exploding to higher highs. Top Stock No. 1 – Inovio Pharmaceuticals (INO) We recommended Inovio Pharmaceuticals on April 15, as it traded at just $7. Then, just last Wednesday, we highlighted it again as an opportunity at $13.55. As of this morning, INO is up to $13.80 and is still an opportunity. [image](#) To date, preclinical data has shown promising immune responses across animal models. "Preclinical results for INOVIO's COVID vaccine have been consistent with completed Phase 1 vaccine study for Middle East Respiratory Syndrome (MERS), also caused by a coronavirus, in which INOVIO's DNA vaccine was well tolerated and induced high levels of antibody responses in 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants,” notes Inovio. H.C. Wainwright for example has a buy rating on the stock with a target of $13. "We find it impressive that Inovio first designed INO-4800 on January 10, within three hours of receiving the viral genetic sequence, and managed to complete preclinical studies and manufacture 3,000 human trial doses in roughly three months... we believe INO-4800 could be ready for a Phase 2 trial and available for emergency use by the end of 2020,” they note. Top Stock No. 2 – Moderna Inc. (MRNA) We recommended Moderna Inc. on April 15, as it traded at $34.52. Then, just last Wednesday, we highlighted it again at $64.05. It’s now up to $86.50 and still running. Moderna (MRNA) is racing to higher highs on news its vaccine produced COVID-19 antibodies in all 45 of its participants. [image](#) “These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 (micrograms),” Tal Zaks, the chief medical officer at Moderna said, as quoted by CNBC. “When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” he added. If the company sees further success, Phase II trials will begin shortly. Phase III could begin shortly after that with thousands of healthy volunteers. [Read More]( Prime Entry Profits (PEP) by [Wendy Kirkland]( [Prime Entry Profits] Thought for the Week: Remember, if you are criticizing, you are not being grateful. If you are blaming, you are not being grateful. If you are complaining, you are not being grateful. If you are feeling tension, you are not being grateful. If you are rushing, you are not being grateful. If you are in a bad mood, you are not being grateful. This Week In Trading: DOW +911, NASDAQ +220, DOW +90. Be sure to check earnings dates. BMY-Bristol Myers – P3.5 HD-Home Depot – P3.5 PYPL-Paypal – P3.5 SNAP-Snap – P3.5 [Read More]( [www.tradewins.com]( [Facebook]( [Twitter]( [LinkedIn]( [Youtube]( [Better Business Bureau]( © Copyright 2020 [TradeWins.com](. All rights reserved. TradeWins Publishing, 22C New Leicester Hwy, #117, Asheville, NC 28806 Email: support@iss-trading.com | Phone: 888-233-1431 | Fax: 888-258-4938 PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: [All About Auto-Trading]( , TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading. 1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis. 2) TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services. 3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber. 4) You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more. 5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities. 6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown. 7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses. 8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk. If you wish to stop receiving our emails or change your subscription options, please [Manage Your Subscription]( TradeWins Publishing, 528 North Country Rd., St. James, NY 11780 If you'd like to unsubscribe and stop receiving these emails [click here](.